1-(1,3-二氧戊环-4-基甲基)哌嗪 | 164331-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(1,3-二氧戊环-4-基甲基)哌嗪
• 英文名称: 1-(1,3-Dioxolan-4-ylmethyl)piperazine
• CAS: 164331-63-9
• 化学式: C₈H₁₆N₂O₂
• 分子量: 172.22
• InChiKey: PNHUKNNXWPVYPN-UHFFFAOYSA-N

物化性质

• 沸点：
  267.4±25.0 °C(Predicted)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  33.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME<br/>[FR] RÉACTIFS DE TRANSFECTION AMINÉS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：LIFE TECHNOLOGIES CORP

  公开号：WO2012068176A1

  公开（公告）日：2012-05-24

  There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.

  本文提供了一种新型含胺转染化合物及其制备和使用方法。这些化合物通常是通过将一级胺与不饱和化合物反应而获得的。本文还提供了使用含胺转染化合物与其他化合物结合以封装生物活性剂（如核酸）制备的转染复合物。还描述了使用转染复合物进行体内或体外传递生物活性剂的方法。本发明的转染复合物具有很高的效力，因此与已知的类似转染化合物相比，可以在相对较低的剂量下有效调节生物活性。
• Compounds inhibiting the aggregation of superoxide dismutase-1
  申请人：Lansbury Peter

  公开号：US20060194821A1

  公开（公告）日：2006-08-31

  The invention is directed to methods of inhibiting the rate at which superoxide dismutse-1 (SOD) aggregates using compounds that stabilize SOD dimers. The methods are useful in the study and therapy of amyotrophic lateral sclerosis. The invention also includes assays that can be used to identify compounds that stabilize dimers and SOD molecules that have been modified for use in these assays.

  本发明涉及使用稳定SOD二聚体的化合物来抑制超氧化物歧化酶-1（SOD）聚集的速率的方法。该方法在进行肌萎缩侧索硬化的研究和治疗中非常有用。本发明还包括可用于识别稳定二聚体化合物和已经改性用于这些测定的SOD分子的测定方法。
• [EN] BIOREDUCIBLE POLY (B-AMINO ESTER)S FOR SIRNA DELIVERY<br/>[FR] POLY(ESTER B-AMINO) BIORÉDUCTIBLE POUR L'ADMINISTRATION D'ARNSI
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2014066811A1

  公开（公告）日：2014-05-01

  Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and/or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and/or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases.

  合成了可降解聚合物，可与核酸、蛋白质、疏水药物和其他小分子自组装形成颗粒，有效地输送到细胞、组织和/或生物体内，无论在体外还是体内。目前披露的聚合物表现出细胞类型特异性差异，能够促进内体逃逸以保护货物免受降解并增强输送到细胞质的能力和/或生物还原性，使触发的细胞内药物释放可调节以促进最佳输送到目标细胞类型。目前披露的材料可用于治疗各种疾病或病症，例如癌症、心血管疾病、传染病和眼科疾病。
• [EN] 3'-N-MODIFIED 6-O-SUBSTITUTED ERYTHROMYCIN KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY<br/>[FR] DERIVES D'ERYTHROMYCINE CETOLIDEE, MODIFIES EN 3'-N ET SUBSTITUES EN 6-O, POSSEDANT UNE ACTIVITE ANTIBACTERIENNE
  申请人：ABBOTT LABORATORIES

  公开号：WO1999016779A1

  公开（公告）日：1999-04-08

  (EN) Novel 3'-N-modified 6-O-substituted erythromycin ketolide compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I), (II), (III), (IV) or (V), compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, as well as a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention.(FR) Nouveaux dérivés d'érythromycine cétolidée, modifiés en 3'-N et substitués en 6-O, ainsi que leurs sels et leurs esters pharmaceutiquement acceptables, possédant une activité antibactérienne, de formule (I), (II), (III), (IV) ou (V); compositions renfermant une quantité, efficace sur le plan thérapeutique, d'un composé de l'invention, associé à un véhicule pharmaceutiquement acceptable; et méthode permettant de traiter des infections bactériennes en administrant à un mammifère une composition pharmaceutique qui contient une quantité, efficace sur le plan thérapeutique, d'un composé de l'invention.

  （中文翻译）本发明涉及一种新型的3'-N-修饰的6-O-取代的红霉素酮内酯类化合物，以及其具有抗菌活性的药学上可接受的盐和酯，其化学式为(I)、(II)、(III)、(IV)或(V)；包含本发明化合物的治疗有效量与药学上可接受的载体相结合的组合物；以及通过向哺乳动物投与含有本发明化合物的治疗有效量的药物组合物来治疗细菌感染的方法。
• [EN] 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY<br/>[FR] CETOLIDES SUBSTITUES EN 6-O POSSEDANT UNE ACTIVITE ANTIBACTERIENNE
  申请人：ABBOTT LABORATORIES

  公开号：WO1998009978A1

  公开（公告）日：1998-03-12

  (EN) Antimicrobial compounds having formula (II), (III), (IV), (IV-A) or (V) as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compunds.(FR) L'invention concerne des composés antimicrobiens de la formule: (II); (III); (IV); (IV-A); ou (V); ainsi que des sels, esters ou promédicaments de ceux-ci, acceptables d'un point de vue pharmaceutique; des compositions pharmaceutiques comprenant de tels composés; des procédés destinés à traiter des infections bactériennes par l'administration de tels composés; et des procédés destinés à la préparation de ces composés.

  (中文) 具有公式(II)、(III)、(IV)、(IV-A)或(V)的抗微生物化合物，以及其在药学上可接受的盐、酯或前药；包括这些化合物的制药组合物；通过给予这些化合物进行治疗细菌感染的方法；以及这些化合物的制备方法。